Carey Robert M, Siragy Helmy M
Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Box 801414, University of Virginia Health System, Charlottesville, VA 22908-1414, USA.
Trends Endocrinol Metab. 2003 Aug;14(6):274-81. doi: 10.1016/s1043-2760(03)00111-5.
The renin-angiotensin system (RAS) is a coordinated cascade of proteins and peptide hormones, the principal effector of which is angiotensin II (ANG II). Evidence now indicates that the kidney regulates its function via a self-contained RAS in a paracrine fashion. In diabetic nephropathy, the intrarenal generation of ANG II is increased, in spite of suppression of the systemic RAS. This increase can contribute to the progression of diabetic nephropathy via several hemodynamic, tubular and growth-promoting actions. ANG II induces insulin resistance. ANG II type-1 (AT(1)) and type-2 (AT(2)) receptors are downregulated in chronic diabetes, but decreased AT(2) receptor expression might contribute to early diabetic nephropathy by reducing AT(2) receptor-mediated beneficial actions that are counter-regulatory to those of the AT(1) receptor. AT(2) receptor stimulation might account for part of the renal protection seen with AT(1) receptor blockade. A rat model of accelerated diabetic nephropathy is the (mREN-2) 27 renin transgenic rat treated with streptozotocin in which both the intrarenal and extrarenal RAS is activated.
肾素-血管紧张素系统(RAS)是由蛋白质和肽类激素组成的协调级联反应,其主要效应因子是血管紧张素II(ANG II)。目前有证据表明,肾脏通过自分泌的RAS以旁分泌方式调节自身功能。在糖尿病肾病中,尽管全身RAS受到抑制,但肾脏内ANG II的生成仍会增加。这种增加可通过多种血液动力学、肾小管及促生长作用促进糖尿病肾病的进展。ANG II可诱导胰岛素抵抗。在慢性糖尿病中,1型血管紧张素II(AT(1))受体和2型血管紧张素II(AT(2))受体下调,但AT(2)受体表达降低可能通过减少AT(2)受体介导的与AT(1)受体作用相反的有益作用而导致早期糖尿病肾病。刺激AT(2)受体可能是AT(1)受体阻断所产生的部分肾脏保护作用的原因。加速型糖尿病肾病大鼠模型是用链脲佐菌素处理的(mREN-2)27肾素转基因大鼠,其肾脏内和肾脏外的RAS均被激活。